Kirin Company
Search results
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. Its flagship business Kyowa Kirin Co., Ltd. creates antibody-based drugs for cancer, kidney disease, and immune system diseases.
Kyowa Kirin pursues scientific breakthroughs to address unmet clinical needs. Learn more about our portfolio of specialty medicines in nephrology, oncology, immunology & allergy, and neurology. Join us to grow your career or partner with us to propel your research discoveries into the hands of patients and physicians.
Jan 1, 2024 · IR Events. This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.
At Kyowa Kirin, our Core Values drive us to do everything we can to answer the needs of patients, their families, and medical professionals. We act consistently with these Core Values in mind – Commitment to Life, Innovation, Integrity, and Teamwork/Wa.
By locating its new site in the midst of North Carolina’s robust life sciences hub, Kyowa Kirin will benefit from a thriving network of biomanufacturing resources as well as a rich pool of talent within the greater Research Triangle Park region, the largest research park in the United States.
Jan 1, 2024 · Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 First Quarter （1,729KB）. Results Presentation Fiscal 2023 First Quarter （1,175KB）. Transcript of Results Briefing Fiscal 2023 First Quarter （1,673KB）.
Learn how our offices in NJ, California and Ontario focus on discovery, product development, and commercialization. Together, we work as a team to understand clinical needs and advance innovations that can have a profound impact on patients’ lives.
Across North America and around the globe, Kyowa Kirin strives to create and deliver novel medicines with life-changing value. We are a Japan-based global specialty pharmaceutical company that uses cutting-edge science to address the needs of patients across multiple therapeutic areas.
Cumberland Pharmaceuticals Acquires Sancuso® from Kyowa Kirin North America. Nashville-based pharmaceutical company will acquire U.S. rights from Japan-based Kyowa Kirin. SANCUSO® is an established, FDA-Approved Oncology Supportive Care Medicine.
Advance your career in pharmaceutical technology including pharmaceutical research, manufacturing, drug and product development, and more. Our growth relies on sharing expertise and ideas in ways that prioritize innovation, diversity, teamwork, and integrity. Join us to create a profound impact.
